Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 11/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25865063 | 0.79 | ALDH1A1 (0.43) | MEN1KMT2AALDH1A1SMN1; SMN2PIK3CG | |
| SCHEMBL25865064 | 0.79 | ALDH1A1 (0.43) | KDM4EALDH1A1SMN1; SMN2PIK3CG | |
| SCHEMBL21369617 | 0.73 | MEN1 (0.47) | MEN1CYP2D6KMT2ADHFREGFR | |
| SCHEMBL21369471 | 0.73 | MEN1 (0.47) | MEN1CYP2D6KMT2ADHFREGFR | |
| SCHEMBL3198772 | 0.73 | RAD52 (0.36) | CYP2D6KDM4EALDH1A1 | |
| SCHEMBL20434754 | 0.72 | MEN1 (0.49) | MEN1CYP2D6KMT2ADHFREGFR | |
| SCHEMBL21370312 | 0.71 | CYP2D6 (0.72) | MEN1CYP2D6KMT2AKDM4EALDH1A1 | |
| SCHEMBL12894237 | 0.70 | PIK3CG (0.54) | ALDH1A1PIK3CG | |
| SCHEMBL24862856 | 0.70 | CYP2D6 (0.75) | MEN1CYP2D6KMT2AKDM4EALDH1A1 | |
| SCHEMBL6173475 | 0.69 | CLK1 (0.44) | MEN1KMT2AALDH1A1SMN1; SMN2PIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666879-B2 | Imidazo[1,2-A]pyridine compounds as VEGF-R2 inhibitors | ELI LILLY AND COMPANY (US) | 2010-02-23 | — | — | US | disclosed |
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227622-A1 | IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS | KDR, FLT1, FLT4 | MEN1 3045/4885CYP2D6 2202/4885KMT2A 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.